Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
PRJ-13024 by Guangzhou Yinming Biomedical Technology for Metastatic Melanoma: Likelihood of Approval
PRJ-13024 is under clinical development by Guangzhou Yinming Biomedical Technology and currently in Phase I for Metastatic Melanoma. According to...
Data Insights
PRJ-13024 by Guangzhou Yinming Biomedical Technology for Colon Cancer: Likelihood of Approval
PRJ-13024 is under clinical development by Guangzhou Yinming Biomedical Technology and currently in Phase II for Colon Cancer. According to...